메뉴 건너뛰기




Volumn 106, Issue 7, 2006, Pages 2794-2810

Emerging technologies supporting chemical process R and D and their increasing impact on productivity in the pharmaceutical industry

Author keywords

[No Author keywords available]

Indexed keywords

ENGINEERING RESEARCH; ENZYME IMMOBILIZATION; INDUSTRY; KINETIC THEORY; MOLECULAR STRUCTURE; REACTION KINETICS;

EID: 33746914340     PISSN: 00092665     EISSN: None     Source Type: Journal    
DOI: 10.1021/cr040674i     Document Type: Review
Times cited : (97)

References (187)
  • 1
    • 0003812821 scopus 로고    scopus 로고
    • Harvard Business School Press: Boston, MA
    • Pisano, G. The Development Factory; Harvard Business School Press: Boston, MA, 1997; p 36.
    • (1997) The Development Factory , pp. 36
    • Pisano, G.1
  • 8
    • 33746898818 scopus 로고    scopus 로고
    • (accessed 5/2)
    • www.reactarray.com (accessed 5/2/2006).
    • (2006)
  • 14
    • 33746928924 scopus 로고    scopus 로고
    • Using Factorial Experiments in the Development of Process Chemistry
    • In Gadamasetti, K. G., Ed.; Dekker: New York
    • Pilipauskas, D. R. Using Factorial Experiments in the Development of Process Chemistry. In Process Chemistry in the Pharmaceutical Industry; Gadamasetti, K. G., Ed.; Dekker: New York, 1999; pp 411-428.
    • (1999) Process Chemistry in the Pharmaceutical Industry , pp. 411-428
    • Pilipauskas, D.R.1
  • 42
    • 33746870568 scopus 로고    scopus 로고
    • (accessed 5/2)
    • http://www.mt.com/autochem/ (accessed 5/2/2006).
    • (2006)
  • 43
    • 33746889596 scopus 로고    scopus 로고
    • (accessed 5/2)
    • http://www.barnsteadthermolyne.com/labline1.cfm?ProdLine=STEM (accessed 5/2/2006).
    • (2006)
  • 44
    • 33746869830 scopus 로고    scopus 로고
    • (accessed 5/2)
    • http://www.helgroup.com/ (accessed 5/2/2006).
    • (2006)
  • 48
    • 33746923261 scopus 로고    scopus 로고
    • Example companies providing reaction and catalyst screening capabilities include Solvias and Avantium (http://www.avantium.com)
    • Example companies providing reaction and catalyst screening capabilities include Solvias (http://www.solvias.com) and Avantium (http://www.avantium.com).
  • 71
    • 18844444146 scopus 로고    scopus 로고
    • In Hagemeyer, A., Strasser, P., Volpe, A. F., Jr., Eds.; Wiley-VCH: Weinheim
    • In High-Throughput Screening in Chemical Catalysis; Hagemeyer, A., Strasser, P., Volpe, A. F., Jr., Eds.; Wiley-VCH: Weinheim, 2004.
    • (2004) High-Throughput Screening in Chemical Catalysis
  • 76
    • 33746882611 scopus 로고    scopus 로고
    • (accessed 5/2)
    • http://www.symyx.com (accessed 5/2/2006).
    • (2006)
  • 77
    • 33746901428 scopus 로고    scopus 로고
    • (accessed 5/2)
    • http://www.biotage.com (accessed 5/2/2006).
    • (2006)
  • 89
    • 33746887578 scopus 로고    scopus 로고
    • Common limits for controlling and qualifying impurities in APIs are described in the International Committee for Harmonization (ICH) guideline Q3A(R), which can be found at (accessed 2/25)
    • Common limits for controlling and qualifying impurities in APIs are described in the International Committee for Harmonization (ICH) guideline Q3A(R), which can be found at http://www.ich.org/cache/compo/ 276-254-1.html (accessed 2/25/2005).
    • (2005)
  • 90
    • 3042602402 scopus 로고    scopus 로고
    • The term "impurity profiling" as it relates to pharmaceutical research and development is commonly used to describe work associated with detection, isolation/structure elucidation, and quantification of impurities in API and pharmaceutical formulations, For a more thorough overview
    • The term "impurity profiling" as it relates to pharmaceutical research and development is commonly used to describe work associated with detection, isolation/structure elucidation, and quantification of impurities in API and pharmaceutical formulations, For a more thorough overview, see: Gorog, S. Trends Anal. Chem. 2003, 22 (7), 407.
    • (2003) Trends Anal. Chem. , vol.22 , Issue.7 , pp. 407
    • Gorog, S.1
  • 91
    • 0033128171 scopus 로고    scopus 로고
    • For an extensive review of LC/MS and its evolving role in pharmaceutical research and development
    • For an extensive review of LC/MS and its evolving role in pharmaceutical research and development, see: Lee, M. S.; Kearns, E. H. Mass Spectrom. Rev. 1999, 18 (3/4), 187.
    • (1999) Mass Spectrom. Rev. , vol.18 , Issue.3-4 , pp. 187
    • Lee, M.S.1    Kearns, E.H.2
  • 116
    • 27144553465 scopus 로고    scopus 로고
    • (Handbook of Pharmaceutical Analysis by HPLC)
    • Wann, M. H. Sep. Sci. Technol. 2005, 6 (Handbook of Pharmaceutical Analysis by HPLC), 569.
    • (2005) Sep. Sci. Technol. , vol.6 , pp. 569
    • Wann, M.H.1
  • 122
    • 33746881587 scopus 로고    scopus 로고
    • note
    • From the chemist's perspective, the study of reaction rates and mechanisms involves the field of physical chemistry; from the chemical engineer's perspective, the same studies are considered a branch of reaction engineering.
  • 123
    • 33845281011 scopus 로고
    • For a classic example of mechanistic detail deduced from kinetic studies of a complex reaction involving catalysis
    • For a classic example of mechanistic detail deduced from kinetic studies of a complex reaction involving catalysis, see: Landis, C. R.; Halpern, J. J. Am. Chem. Soc. 1987, 109 (6), 1746.
    • (1987) J. Am. Chem. Soc. , vol.109 , Issue.6 , pp. 1746
    • Landis, C.R.1    Halpern, J.2
  • 125
    • 0346218217 scopus 로고    scopus 로고
    • A recent example of rate acceleration proposed on the basis of mechanistic knowledge is the proposed use of tethered "hemi-labile" ligands, as reported in the following
    • A recent example of rate acceleration proposed on the basis of mechanistic knowledge is the proposed use of tethered "hemi-labile" ligands, as reported in the following: Ramirez, A.; Lobkovsky, E.; Collum, D. B. J. Am. Chem. Soc. 2003, 125 (50), 15376.
    • (2003) J. Am. Chem. Soc. , vol.125 , Issue.50 , pp. 15376
    • Ramirez, A.1    Lobkovsky, E.2    Collum, D.B.3
  • 127
    • 33746930059 scopus 로고    scopus 로고
    • (accessed 2/25)
    • http://www.fda.gov/cder/gmp/gmp2004/GMP_finalreport2004.htm (accessed 2/25/2005).
    • (2005)
  • 128
    • 33746914901 scopus 로고    scopus 로고
    • (accessed 2/25)
    • http://www.fda.gov/cder/guidance/6452dft.htm (accessed 2/25/2005).
    • (2005)
  • 137
    • 17144379618 scopus 로고
    • For a discussion of an early progenitor of BatchCAD
    • For a discussion of an early progenitor of BatchCAD, see: Wright, A.; Bramfitt, V. Chem. Ind. 1988, 4, 114.
    • (1988) Chem. Ind. , vol.4 , pp. 114
    • Wright, A.1    Bramfitt, V.2
  • 140
    • 33746932300 scopus 로고    scopus 로고
    • In Green, A., Ed.; BHR Group Conference Series; Professional Engineering Publ. Ltd.: Bury St. Edmunds, U.K
    • In Process Intensification for the Chemical Industry: Smaller, Cheaper and Safer; Green, A., Ed.; BHR Group Conference Series; Professional Engineering Publ. Ltd.: Bury St. Edmunds, U.K.; 1999.
    • (1999) Process Intensification for the Chemical Industry: Smaller, Cheaper and Safer
  • 155
    • 33746919761 scopus 로고    scopus 로고
    • (accessed 2/25)
    • See http://www.protensive.co.uk/ (accessed 2/25/2005).
    • (2005)
  • 164
    • 0003428180 scopus 로고    scopus 로고
    • In Ehrfeld, W., Hessel, V., Lowe, H., Eds.; WILEY-VCH Verlag GmbH: Weinheim
    • In Microreactors: New Technology for Modern Chemistry; Ehrfeld, W., Hessel, V., Lowe, H., Eds.; WILEY-VCH Verlag GmbH: Weinheim, 2000.
    • (2000) Microreactors: New Technology for Modern Chemistry


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.